- Stocks
- Pharma & Healthcare
- Ambalal Sarabhai Enterprises
Ambalal Sarabhai Enterprises share price
NSE: AMBALALSAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Ambalal Sarabhai Enterprises at a glance
Ambalal Sarabhai Enterprises (NSE: AMBALALSA) closed at ₹38.00 on 21 Oct 2026, down 2.44% on the day. With a market capitalisation of ₹291 Cr, it ranks 2072nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 16.4× trailing earnings, against a return on equity of 11.2% in FY26. Its 52-week range is ₹30.15 (23 Jul 2026) to ₹49.98 (10 Aug 2026); the last close is 24.0% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹65 Cr (+1.0% year on year) and net profit ₹6 Cr, on a consolidated basis. Promoters held 31.36% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹291 CrRank 2072 on NSE
- P/E (trailing)
- 16.4×
- Price to book
- 1.17×FY26
- EPS (TTM)
- ₹2.25to Q4 FY26
- ROE
- 11.2%FY26
- ROCE
- 12.6%FY26
- Debt to equity
- 0.33FY26
- Net profit margin
- 8.6%FY26
- Book value / share
- ₹20.66FY26
- 52-week high
- ₹49.9810 Aug 2026
- 52-week low
- ₹30.1523 Jul 2026
- RSI (14-day)
- 43.1
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.44% | −1.3% | −4.0% | +18.8% | — |
Ambalal Sarabhai Enterprises quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹41 Cr | ₹45 Cr | ₹46 Cr | ₹65 Cr | ₹40 Cr | ₹44 Cr | ₹52 Cr | ₹65 Cr |
| Revenue YoY | +12.7% | +11.7% | +6.6% | +19.2% | −0.9% | −0.6% | +13.1% | +1.0% |
| Net profit | ₹1 Cr | ₹2 Cr | ₹2 Cr | −₹0 Cr | ₹8 Cr | −₹0 Cr | ₹3 Cr | ₹6 Cr |
| Net profit YoY | — | +46.9% | +94.4% | −101.5% | +1,060.6% | −124.7% | +66.3% | — |
| Net margin | 1.7% | 3.7% | 4.5% | −0.2% | 20.4% | −0.9% | 6.7% | 9.3% |
| EPS | ₹0.05 | ₹0.34 | ₹0.29 | −₹0.04 | ₹1.07 | −₹0.07 | ₹0.40 | ₹0.85 |
Ambalal Sarabhai Enterprises financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹164 Cr | ₹197 Cr | ₹170 Cr | ₹174 Cr | ₹196 Cr | — |
| Operating profit | ₹23 Cr | ₹63 Cr | ₹16 Cr | ₹9 Cr | ₹11 Cr | — |
| Net profit | ₹20 Cr | ₹41 Cr | ₹12 Cr | ₹8 Cr | ₹4 Cr | — |
| EPS (₹) | ₹4.00 | ₹6.00 | ₹1.00 | ₹1.00 | ₹1.00 | — |
| Cash from operations | −₹2 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | −₹18 Cr | — |
| Total debt | ₹5 Cr | ₹3 Cr | ₹18 Cr | ₹9 Cr | ₹8 Cr | ₹18 Cr |
| Shareholders' equity | ₹74 Cr | ₹120 Cr | ₹131 Cr | ₹137 Cr | ₹140 Cr | ₹158 Cr |
Ambalal Sarabhai Enterprises shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 31.35% | 31.35% | 31.35% | 31.36% | 31.36% | 31.36% |
| Domestic institutions | 0.10% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 68.17% | 68.27% | 68.31% | 68.29% | 68.64% | 68.64% |
Ambalal Sarabhai Enterprises vs peers
The listed Pharma & Healthcare companies nearest to Ambalal Sarabhai Enterprises by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LYKALABSLyka Labs | ₹86.04 | −1.99% | −9.0% | ₹311 Cr | — | — |
| NURECANureca | ₹319.00 | +0.60% | +35.1% | ₹304 Cr | 150.5 | — |
| BIJHANSBijoy Hans | — | — | — | ₹292 Cr | — | — |
| AMBALALSAAmbalal Sarabhai Enterprises | ₹38.00 | −2.44% | — | ₹291 Cr | 16.4 | — |
| ASTONEALABAstonea Labs | — | — | — | ₹281 Cr | — | — |
| ESPIREEspire Hospital | — | — | — | ₹274 Cr | — | — |
| ZENOTECHZenotech Labs | — | — | — | ₹270 Cr | — | — |
Ask anything about Ambalal Sarabhai Enterprises
Pivot answers on the live chart with evidence you can check, and tests strategies against AMBALALSA's own history. Try: “Why has AMBALALSA moved over the last three months?” · “Backtest a 50-day moving-average crossover on AMBALALSA over five years” · “Compare AMBALALSA with LYKALABS on margins and valuation”
Frequently asked questions about Ambalal Sarabhai Enterprises
What is the share price of Ambalal Sarabhai Enterprises today?
Ambalal Sarabhai Enterprises (NSE: AMBALALSA) last closed at ₹38.00 on 21 Oct 2026. Its 52-week high is ₹49.98 and its 52-week low is ₹30.15.
What is the market cap of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises' market capitalisation is ₹291 Cr (₹291 Cr) at the 21 Oct 2026 close, ranking 2072nd among the NSE companies Pivot tracks.
What is the P/E ratio of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises trades at a trailing P/E of 16.4.
What is the ROE and ROCE of Ambalal Sarabhai Enterprises?
Return on equity was 11.2% in FY26 and return on capital employed was 12.6% in FY26 (consolidated figures).
Is Ambalal Sarabhai Enterprises a debt-free company?
No. Ambalal Sarabhai Enterprises' debt-to-equity ratio was 0.33 in FY26, with total debt of ₹18 Cr.
What were Ambalal Sarabhai Enterprises' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Ambalal Sarabhai Enterprises reported revenue of ₹65 Cr, +1.0% year on year, and net profit of ₹6 Cr.
What is the shareholding pattern of Ambalal Sarabhai Enterprises?
As of 30 Jun 2026: promoters 31.36%, domestic institutions 0.01%, non-institutions 68.64%.
Who are Ambalal Sarabhai Enterprises' competitors?
The listed Pharma & Healthcare companies closest to Ambalal Sarabhai Enterprises by market cap are Lyka Labs, Nureca, Bijoy Hans, Astonea Labs, Espire Hospital and Zenotech Labs.
Is Ambalal Sarabhai Enterprises a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Ambalal Sarabhai Enterprises' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AMBALALSA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text